Till innehåll

Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

 

Nasdaq Stockholm

Price

Change

WEBCAST

Invitation to presentation of the Q3 report 2026

Oncopeptides AB published the report for the third quarter 2026, at 08:00 CET November 5, 2026. Investors, financial analysts, and media were invited to participate in a webcast and a subsequent Q&A session on November 5 at 09:00 CET.

Latest investor news

November 9, 2026

European Commission approves label expansion of Pepaxti to third-line treatment

Regulatory
Read more
November 5, 2026

Oncopeptides publishes Q3 report 2026

November 4, 2026

New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026

October 30, 2026

Number of shares and votes in Oncopeptides

No upcoming events

Investor Relations Contact

David Augustsson, MSc
Director of IR and Communications

More investor information

The share

General Meeting

Financial Reports

Financial Calendar

Select language or region
Region

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care

Learn more about the company Oncopeptides and the work we do to redefine cancer care